OCUL
Ocular Therapeutix, Inc.NASDAQHealthcare$8.49+1.92%ClosedMarket Cap: $1.85B
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
2.75
P/S
33.82
EV/EBITDA
-4.39
DCF Value
$-0.59
FCF Yield
-12.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
87.3%
Operating Margin
-519.8%
Net Margin
-511.9%
ROE
-71.7%
ROA
-32.9%
ROIC
-35.5%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $13.3M | 88.0% | $-69.8M | $-64.7M | $-0.29 | — |
| FY 2025 | $51.8M | 87.3% | $-270.0M | $-265.9M | $-1.42 | — |
| Q3 2025 | $14.5M | 87.8% | $-68.7M | $-69.4M | $-0.38 | — |
| Q2 2025 | $13.5M | 85.6% | $-67.6M | $-67.8M | $-0.39 | — |
| Q1 2025 | $10.7M | 88.2% | $-63.9M | $-64.1M | $-0.38 | — |
| Q4 2024 | $17.1M | 92.8% | $-50.6M | $-48.4M | $-0.29 | — |
| FY 2024 | $63.7M | 91.2% | $-171.8M | $-193.5M | $-1.22 | — |
| Q3 2024 | $15.4M | 89.9% | $-46.0M | $-36.5M | $-0.22 | — |
| Q2 2024 | $16.4M | 90.8% | $-43.6M | $-43.8M | $-0.26 | — |
| Q1 2024 | $14.8M | 91.0% | $-31.6M | $-64.8M | $-0.49 | — |
| Q4 2023 | $14.8M | 90.6% | $-20.1M | $-29.2M | $-0.20 | — |
| FY 2023 | $58.4M | 91.0% | $-82.4M | $-80.7M | $-1.02 | — |